RESEARCH

Using DNA testing for the precise, definite, and low-cost diagnosis of sickle cell disease and other Haemoglobinopathies: findings from Tanzania

Heavenlight Christopher1†, Adam Burns2†, Emmanuel Josephat1, Julie Makani1, Anna Schuh1,2† and Siana Nkya1,3†

Abstract

Background: Sickle cell disease (SCD) is an important cause of under-five mortality. Tanzania is the 5th country in the world with the highest births prevalence of SCD individuals. Significant advances in the neonatal diagnosis of SCD using rapid point-of-care testing have been made. However genetic confirmation is still required for positive cases, in uncertain cases, in multiply transfused patients, to resolve compound heterozygosity (Hb S/β0 Thal or Hb S/β+ thal) not uncommon in the coastal regions of East Africa and increasingly also for pre-marital counselling and potentially for future curative approaches such as gene therapy. The currently available DNA tests are prohibitively expensive. Here, we describe an easy-to-use, affordable and accurate β-globin sequencing approach that can be easily integrated within existing NBS for SCD and other haemoglobinopathies especially in Low- and Middle-income Countries.

Aim: To evaluate an affordable DNA technology for the diagnosis of Sickle cell disease and other haemoglobinopathies in a resource-limited setting.

Methods: Laboratory-based validation study was conducted by Muhimbili University of Health and Allied Sciences and the University of Oxford involving sequencing of the entire β-haemoglobin locus using the Oxford Nanopore MinION platform. A total number of 36 Dried blood spots and whole blood samples were subjected to conventional protein-based methods (isoelectric focusing, HPLC), and/or sequenced by the Sanger method as comparators.

Results: Sequencing results for SCD using the MinION were 100% concordant with those from the Sanger method. In addition, the long-read DNA sequencing method enabled the resolution of cases with unusual phenotypes which make up 1% of all children in Tanzania. The cost is £11/sample for consumables, which is cheaper compared to other sequencing platforms.

Conclusions: This is the first report of a comprehensive single DNA assay as a definitive diagnostic test for SCD and other haemoglobinopathies. The test is fast, precise, accurate and affordable.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Sickle cell disease (SCD) refers to a group of inherited red blood cell disorders that occur due to mutations in β-globin genes, one of which is invariably haemoglobin S (HbS), a variant produced as a result of glutamic acid to valine substitution at position 6 of the beta-globin chain, the underlying mutation being HBB: c.20A > T. Deoxy-HbS is prone to polymerization, disrupting red blood cell shape, function, and life span. HbS can be co-inherited with β-thalassaemia and other haemoglobin variants that might impact clinical phenotypes. SCD is generally characterized by chronic haemolytic anaemia and recurrent vaso-occlusions, leading to painful crises, multi-organ impairment, and sometimes premature death [1, 2].

Worldwide it is estimated that >300,000 babies are born annually with SCD and that these numbers will likely increase to 404,200 in 2050 [3]. Most of these babies are born in sub-Saharan Africa and India [4–6], where SCD contributes significantly to early childhood mortality and morbidity [7, 8]. In 2006, the WHO, at its 59th health assembly, declared SCD as a significant public health burden in Africa [9, 10].

Currently, the diagnosis of SCD and other haemoglobinopathies relies on protein-based assays with isoelectric focusing (IEF) as the first-line sickle cell screening test, followed by confirmation of positive cases by high-performance liquid chromatography (HPLC) as a second-line screening method. Although these are standard methods, they require transport of the sample to a central laboratory, expensive equipment, experienced operating personnel and genetic confirmation of positive cases. Point-of-care (POC) immunoassay methods, such as Sickle SCAN and HemoTypeSC, detect the altered sickle epitope of the beta chain and have greatly facilitated neonatal screening through rapid identification of likely affected babies in high-prevalence regions from dried blood spots (DBS) from a heel prick performed shortly after birth. However, they only provide a qualitative result of the presence or absence of Hb A, S, and C, cannot diagnose other haemoglobinopathies [11–16] and require confirmatory testing.

The capacity for genetic testing for SCD and other haemoglobinopathies in Africa is largely limited. In addition to confirmation of positive cases, it is also important to (1) resolve uncertain or complex cases that make up about 1% of cases overall, for example, multiply transfused patients or compound heterozygous individuals (Hb S/β0 Thal or Hb S/β+ thal), (2) inform pre-marital counselling and (3) identify suitable candidates for curative approaches such as gene therapy. However, conventional genetic testing using different PCR approaches and Sanger sequencing is labour intensive and further adds to the complexity and cost of current protein-based laboratory methods.

In the current study, we, therefore, focused on developing an assay and evaluating the use of nanopore sequencing technology as an affordable, low-maintenance genetics test. Single-molecule, or third-generation, sequencing, such as that offered by the MinION platform (Oxford Nanopore Technologies, Oxford, UK) enables the sequencing of DNA of long linear read lengths (1-100kbp). This capability, in combination with the rapid sequencing times, the low initial capital cost required for equipment and maintenance, makes the MinION an attractive DNA sequencing device for the genetic characterisation of SCD and beta-haemoglobinopathies that will greatly facilitate future research efforts based in low- and middle-income-countries [17].

Materials and methods

Study design and area

This was a laboratory-based validation study involving newborns and adults at Muhimbili National Hospital (MNH) and Temeke Regional Hospital, Dar es Salaam, Tanzania. MNH is the national tertiary health facility and has been offering SCD services, both clinical and laboratory, for the past three decades. Temeke Regional Hospital, is a referral hospital for the Temeke municipality in Dar es Salaam, Tanzania, which has recently established SCD services. Both MNH and Temeke Regional Hospital each provide services for residents in Dar es Salaam and the neighbouring regions.

Study population

This study involved 18 DB samples from newborns screened by conventional testing with IEF and/or HPLC and were found to be either homozygous or heterozygous for sickle cell disease or had an unidentified haemoglobin band/variant by IEF and HPLC. In addition to recruiting newborns from the SCD screening programme, we identified 18 patients from the adult haematology clinics at MNH, Temeke and archiveduffy coat from previous SCD study: 2 had sickle trait (Hb AS) but described painful crisis and anaemia, 4 were members of the same family with a history of anaemia and suspected thalassemia and 12 with confirmed...
HbS/β⁺ thalassemia. Demographic and contact details were collected before the collection of the blood sample using a standard proforma and these were later entered into a project database developed in MySQL (Sun Microsystems Inc., Santa Clara, CA, USA). Purposive sampling was used to select individuals who participated in this study.

To test the performance of the assay on DNA from both whole-blood and DBS samples, we grouped our samples into two validation cohorts and a discovery cohort (Fig. 1a). The first validation cohort comprised the 6 individuals from the adult haematology clinics, with DNA extracted from whole blood samples. The second validation cohort consisted of 9 newborn samples, with DBS derived DNA. All samples in the validation cohorts had been previously screened by IEF and HPLC (Table 1). The discovery cohort consisted of an additional 6 newborn DBS and 12 adult whole-blood samples (Table 2).

**Dried blood spot collection**

The DBS samples were collected from newborn heel pricks using standard lancets. DBS collection, transportation, and storage were performed according to the manufacturer’s protocols (Lasec Diagnostics, Ndabeni, South Africa) and NBS guidelines from the Clinical and Laboratory Standards Institute [18].

**Whole blood collection**

Four millilitres of whole blood were collected from each participant into an ethylenediaminetetraacetic acid (EDTA) tube at the Haematology Clinical Research Laboratory (HCRL) by venepuncture, according to HCRL Blood collection SOP version 01. The samples were tested for full blood picture (FBP) by Sysmex XT 2000i haematology analyser and haemoglobin subtyping and quantification by Bio-rad variant NBS HPLC. Also, the buffy coat was isolated by centrifugation of samples at 3000 rpm for 10 min and stored at -80 °C until use.

![Fig. 1](image-url) Details of the experimental methods used for both validation and discovery cohorts. A The validation cohort was selected for a mixture of confirmed clinical diagnoses and both WB and DBS sources. The discovery cohort comprised 9 dB and 12 WB samples. B Samples were prepared for sequencing according to DNA source and sequenced on a MinION mk1b instrument. The resulting sequencing reads were processed locally using a pipeline designed to identify constitutional variants in the β-globin gene. SCH = Sickle Cell Heterozygote, B⁺TH = Beta Thalassaemia Heterozygote, BTI = Beta Thalassaemia Intermedia, SCD = Sickle Cell Disease
SCD screening
Screening for SCD was performed at MUHAS HCRL: 3.2 mm of the DBS was punched by an automated DBS puncher (Wallac DBS Puncher) from PerkinElmer, Massachusetts, USA followed by IEF analysis, conducted according to the manufacturer's protocol (Wallac RESOLVE Haemoglobin System). Samples showing abnormal results such as those found with the sickle gene (FAS), those found to be positive for SCD (FS) and those found to have unidentified variants FAV for the first test were re-punched and retested by HPLC. Results were interpreted by a trained laboratory technician and confirmed by the laboratory manager. Confirmed results were entered into the program’s database using the unique sample identification number.

Molecular testing using the ONT Nanopore MinION
DNA was extracted from two 3.2 mm DBS punches or whole blood using QIAamp DNA Blood Min kit (Qiagen, Hilden, Germany) and the process took 1 h and 30 min to complete extraction. All DNA samples were quantified using either a Qubit high-sensitivity assay for DBS samples or a broad range assay for whole blood (Thermo Fisher Scientific, Waltham, MA, USA) and the process took 5 min to complete quantification. The β-globin gene locus was enriched by an in-house method developed at Oxford University, and each sample was given a unique barcode. Samples were quantified by Qubit broad range assay (Thermo Fisher Scientific, Waltham, MA, USA) and pooled in groups of 8–10 in a final concentration of 1 μg. Sequencing tethers and adaptors were ligated and the library was prepared for sequencing according to the SQK-LSK109 protocol (Oxford Nanopore Technologies, Oxford, UK) (Fig. 1b). Sequencing was performed using a FLO-MIN107 flowcell on a MinION mk1b instrument (Oxford Nanopore Technologies, Oxford, UK). Raw sequencing reads were analysed using a bespoke bio-informatics analysis pipeline (Fig. 1b). All variants called were subjected to additional quality filters (minimum depth of coverage: 200, Phred quality score:15. A VAF cut-off of 40–60% for heterozygous, ≥75% for homozygous was applied, based on the range of VAFs of reference single nucleotide polymorphisms across the beta-globin locus.

The methodology is subject to a licensing agreement. More detailed information is available on request.

Results
Validation cohorts
Sequencing on a MinION instrument for 2 h generated 0.4Gb of sequence data across the 6 individuals of the whole-blood validation cohort, with an average depth of 36,000x over the HBB locus and an average quality score of Q20. Genotypes were classified as either heterozygous or homozygous based on their variant allele frequency (VAF) values (40–60% for heterozygous, ≥75% for homozygous). There were 13 germline variants in our WB validation cohort. Of these, 7 were synonymous changes, 2 were non-synonymous and 4 were found to affect the HBB initiation codon. All 6 individuals contained a

| Sample ID | Sample Type | Age | Sex | Hb (g/dl) | MCV (fl) | Hb S | Hb A | Hb F | Hb A2 | Diagnosis from standard test (genetic or IEF) | Concordance with Nanopore sequencing |
|-----------|-------------|-----|-----|-----------|----------|------|------|------|------|-----------------------------------------------|-------------------------------------|
| FH        | WB          | 21  | F   | 12.4      | 78.8     | 36.3 | 55.8 | 3.3  | 3.3  | Sickle cell heterozygote                      | yes                                 |
| G213707J  | WB          | 30  | F   | 10.9      | 51.4     | –    | 80.9 | 1.1  | 7.8  | Beta+ Thal heterozygote                       | yes                                 |
| G213708H  | WB          | 33  | M   | 11.4      | 47.2     | –    | 81.3 | 1.2  | 6.7  | Beta+ Thal heterozygote                       | yes                                 |
| G213709R  | WB          | 5   | F   | 7.9       | 47.3     | –    | 1.7  | 97.9 | 3.8  | Beta Thal intermedia                          | yes                                 |
| G213711L  | WB          | –   | F   | 10.5      | 47.0     | –    | 80.7 | 9.8  | 6.5  | Beta+ Thal heterozygote                       | yes                                 |
| Z         | WB          | 5   | F   | 8.5       | 74.8     | 38.2 | 51.2 | 5.6  | 3.6  | Sickle cell heterozygote                      | yes                                 |
| TMK 1196  | DBS         | –   | –   | –         | –        | 14.2 | 0.0  | 74.8 | 1.6  | Sickle cell disease                           | yes                                 |
| TMK 1258  | DBS         | –   | –   | –         | –        | 5.3  | 6.6  | 82.0 | –    | Sickle cell heterozygote                      | yes                                 |
| TMK 1259  | DBS         | –   | –   | –         | –        | 4.8  | 7.4  | 80.6 | –    | Sickle cell heterozygote                      | yes                                 |
| TMK 1260  | DBS         | –   | –   | –         | –        | 8.1  | 13.0 | 69.1 | 0.5  | Sickle cell heterozygote                      | yes                                 |
| TMK 1267  | DBS         | –   | –   | –         | –        | 3.8  | 4.6  | 83.5 | 1.3  | Sickle cell heterozygote                      | yes                                 |
| TMK 1276  | DBS         | –   | –   | –         | –        | 9.5  | 16.8 | 62.7 | 0.8  | Sickle cell heterozygote                      | yes                                 |
| TMK 1287  | DBS         | –   | –   | –         | –        | 12.4 | 0.0  | 80.6 | 0.5  | Sickle cell disease                           | yes                                 |
| TMK 1345  | DBS         | –   | –   | –         | –        | 12.2 | 0.0  | 78.9 | 1.4  | Sickle cell disease                           | yes                                 |
| TMK 1536  | DBS         | –   | –   | –         | –        | –    | –    | –    | –    | Sickle cell disease                           | yes                                 |

Table 1 Patient characteristics of the validation cohort. Blood samples are not routinely taken for FBC or HPLC as part of newborn SCD screening. ‘–’ = data not collected
homozygous non-pathogenic same-sense polymorphism (average VAF 99.7%, range 99.4–99.9) affecting the His3 residue (HBB; c.T9C). 2 individuals were heterozygous for the pathogenic HBB: c.20A > T mutation associated with SCD, with VAFs of 46 and 50%. 4 individuals were found to have HBB: c.2 T > C mutations, resulting in a loss of the HBB initiation codon. All 4 individuals were part of a single-family group, 2 parents and 2 daughters. Mother, father and 1 daughter were heterozygous for the variant (VAF 56, 44 and 41% respectively), while the remaining daughter was homozygous, with a VAF of 77%. All variants described were also identified by Sanger sequencing (Tables 1 and 2).

The 9 newborn DBS samples were sequenced in two groups, for 2h each, and generated a total of 0.7Gb of sequence data, with an average depth of coverage of 48,000x and an average quality score of Q20. Of the 18 mutations identified, 9 were synonymous and 9 were non-synonymous. A summary of the results is provided in Table 2.

Table 2 Summary of all non-synonymous variants obtained through conventional screening methods, confirmatory Sanger Sequencing, and nanopore sequencing

| Sample ID | Sample Type | Cohort | Results from conventional screening | Results of nanopore sequencing | Final Diagnosis |
|-----------|-------------|--------|-------------------------------------|--------------------------------|-----------------|
|           |             |        | Method | Result | Mutation | Read Depth (x) | VAF | Het/Hom |                          |
| FH        | WB          | Val    | Sanger | Glu7Val (Het) | Glu7Val | 1645           | 0.46 | Het     | Sickle cell heterozygote |
| G213707J  | WB          | Val    | Sanger | Met1Thr (Het) | Met1Thr | 49,715          | 0.56 | Het     | Beta+ thal heterozygote  |
| G213708H  | WB          | Val    | Sanger | Met1Thr (Het) | Met1Thr | 43,165          | 0.44 | Het     | Beta+ thal heterozygote  |
| G213709R  | WB          | Val    | Sanger | Met1Thr (Hom) | Met1Thr | 80,434          | 0.77 | Hom     | Beta+ thal intermedia    |
| G213711L  | WB          | Val    | Sanger | Met1Thr (Het) | Met1Thr | 127,405         | 0.41 | Het     | Beta+ thal heterozygote  |
| Z         | WB          | Val    | Sanger | Glu7Val (Het) | Glu7Val | 4744           | 0.50 | Het     | Sickle cell heterozygote |
| TMK-1196  | DBS         | Val    | IEF    | FS       | Glu7Val | 91,193          | 0.81 | Hom     | Sickle cell disease      |
| TMK-1258  | DBS         | Val    | IEF    | FAS      | Glu7Val | 118,680         | 0.45 | Het     | Sickle cell heterozygote |
| TMK-1259  | DBS         | Val    | IEF    | FAS      | Glu7Val | 46,389          | 0.55 | Het     | Sickle cell heterozygote |
| TMK-1260  | DBS         | Val    | IEF    | FAS      | Glu7Val | 32,431          | 0.55 | Het     | Sickle cell heterozygote |
| TMK-1267  | DBS         | Val    | IEF    | FAS      | Glu7Val | 38,726          | 0.55 | Het     | Sickle cell heterozygote |
| TMK-1276  | DBS         | Val    | IEF    | FAS      | Glu7Val | 41,793          | 0.53 | Het     | Sickle cell heterozygote |
| TMK-1287  | DBS         | Val    | IEF    | FS       | Glu7Val | 86,884          | 0.95 | Hom     | Sickle cell disease       |
| TMK-1345  | DBS         | Val    | IEF    | FS       | Glu7Val | 17,534          | 0.85 | Hom     | Sickle cell disease       |
| TMK-1356  | DBS         | Val    | IEF    | FS       | Glu7Val | 33,070          | 0.93 | Hom     | Sickle cell disease       |
| Sample 144 | WB         | Disc   | Sanger | Beta+ Thal | c.92 + 1G > A | 5849  | 0.44 | Het     | Beta+ Thal, Sickle cell heterozygote |
| Sample 245 | WB         | Disc   | Sanger | Beta+ Thal | Trp38X  | 5817  | 0.40 | Het     | Beta+ Thal, Sickle cell heterozygote |
| Sample 462 | WB         | Disc   | Sanger | Beta+ Thal | Gln40X  | 5934  | 0.47 | Het     | Beta+ Thal, Sickle cell heterozygote |
| Sample 647 | WB         | Disc   | Sanger | Glu7Val (Het) | Glu7Val | 11,078          | 0.49 | Het     | Sickle cell heterozygote |
| Sample 693 | WB         | Disc   | Sanger | Glu7Val (Het) | Glu7Val | 5967  | 0.51 | Het     | Sickle cell heterozygote |
| Sample 926 | WB         | Disc   | Sanger | Glu7Val (Het) | Glu7Val | 6700  | 0.99 | Hom     | Sickle cell disease       |
| Sample 040 | WB         | Disc   | Sanger | Beta+ Thal | Glu7Val | 4847  | 0.45 | Het     | Sickle cell, Beta+ Thal heterozygote |
| Sample 1077 | WB      | Disc   | Sanger | Beta+ Thal | Glu7Val | 3741  | 0.46 | Het     | Sickle cell, Beta+ Thal heterozygote |
| Sample 1221 | WB      | Disc   | Sanger | Beta+ Thal | Glu7Val | 3688  | 0.44 | Het     | Sickle cell, Beta+ Thal heterozygote |
| Sample 832  | WB         | Disc   | Sanger | Beta+ Thal | Glu7Val | 3287  | 0.45 | Het     | Sickle cell, Beta+ Thal heterozygote |
| Sample 750  | WB         | Disc   | Sanger | Beta+ Thal | Glu7Val | 3258  | 0.45 | Het     | Sickle cell, Beta+ Thal heterozygote |
| Sample 1181 | WB         | Disc   | Sanger | Beta+ Thal | Glu7Val | 3111  | 0.46 | Het     | Sickle cell heterozygote |

WB Whole blood, DBS Dried blood spot, Val Validation, Disc Discovery, IEF Isoelectric focussing, Het Heterozygous mutation, Hom Homozygous mutation, VAF Variant allele frequency.
nonsynonymous. All synonymous mutations were His3His variants, including 1 heterozygous (VAF 55%) and 8 homozygous (average VAF 99.3%, range 97.9–99.9%). The SCD-associated HBB; c.20A>T variant was found in all 9 individuals, 5 heterozygous (average VAF 56.6%, range 44.7–72.6%) and 4 homozygous (average VAF 88.6%, range 80.7–95.1%). These variant calls were consistent with previously obtained data from IEF screening (Tables 1 and 2).

Overall, there was 100% concordance for identifying the SCD status between standard tests and Nanopore sequencing. In addition, the Nanopore sequencing approach detected additional variants of clinical significance in the beta-globin locus. There were no sequencing failures that required repeat analysis.

**Discovery cohort**

We then extended our analysis to a discovery cohort of 18 patients, using DNA extracted from both whole blood (n = 12) and dried blood spots (n = 6). Across three sequencing runs, lasting 2 to 4 h, we generated 1Gb of sequence data, with an average quality score of Q20, and an average depth of coverage of 17,599x. There were 44 variants (22 synonymous, 14 nonsynonymous, 6 stop-gains and 2 splice-site) across all 18 individuals (Table 2). Again, all samples contained the common His3His polymorphism, while sample 245 harboured an additional synonymous polymorphism affecting the Lysine residue at position 60 (HBB; c.180G>A). The HBB; c.20A>T mutation was identified in 12 individuals, 1 homozygous and 11 heterozygous, with average VAFs of 94 and 47%, respectively. In 2 patients we identified a heterozygous variant located in the splice-donor region of exon one (HBB; c.92+1G>A) and (HBB; c.92+1G>T), also referred to as IVS1-1G>A and IVS1-1G>T. Stop-gain mutations were found in 2 individuals, both located in exon 2 (HBB; c.114G>A and HBB; c.118C>T), predicted to result in the loss of ~75% of the coding region (Table 2).

As samples 144, 245 and 462 were all also heterozygous for the HBB; p. Glu7Val variant, we used WhatsHap to determine the phasing for each mutation pair. In all three cases we were able to demonstrate that the reference allele at the Glu7 residue is in trans with the alternate allele for the second mutation (HBB; c.92+1G>A, HBB; c.114G>A and HBB; c.118C>T, respectively, Fig. 2). This information is expected to have a significant impact on the phenotype of the patient, and would be missed by a protein-based SCD screening test.

We found no mutation in 6dB samples that were excluded in Table 2 that contain only non-synonymous mutations.

**Cost analysis**

One of the aims of this study was to develop a low-cost assay to screen for sickle cell and β-thalassaemia mutations, which would enable the assay to be adopted in low and middle-income countries (LMIC). As a consequence of amplifying the full β-globin locus in each patient, we were able to incorporate molecular barcodes for each patient during the library preparation stage. This allowed us to sequence multiple samples in a single run, using their barcode sequences to differentiate between them during data analysis. One advantage of the Oxford Nanopore flow cell is that they can be flushed without carry-over, allowing for a second sequencing run, on the same flow cell. On this basis, we prepared 24 samples per library, sequencing 8 libraries per flow cell. Thanks to this approach, we estimate the current cost of the test to be £11.57 per sample for consumables (Table 3). While this does not include hands-on time for library and bioinformatics analysis, the consumable cost compares very favourably with that of other sequencing methods and even with those of IEF and HPLC.

**Discussion**

Increasingly, long-read sequencing methods, in particular Nanopore sequencing, are being used to address questions in clinical research, including whole-genome sequencing [19], targeted sequencing in cancer [20, 21], and genes with complex genomic structure, such as GBA [22]. The advantages of the Nanopore platform over more established techniques, in particular the short turnaround time and low cost of entry, make it an attractive proposition to labs running with limited funds. Our approach allows for the interrogation of different types of mutations across the entire beta-globin locus causing SCD or thalassaemia, including point mutations, stop gains, and deletions.

We show that Nanopore sequencing confirms heterozygous and homozygous haemoglobin variants, including identification of 100% of carriers of sickle cell variants. Moreover, we identify a family with the IVS1-1G>A mutation that has been shown to inactivate the IVS1 5’ splice site: as a consequence, three nearby cryptic splice sites are used [23], resulting in incorrectly spliced RNA, and a β0-thal phenotype. Little is known about the prevalence of thalassaemia in Sub-Saharan Africa and the underlying genetic mutations. The IVS1G>A mutation is found in patients of Arabic descent, and it is, therefore, plausible that it also occurs along the coastal region of East Africa. Our methodology would be ideally suited to study the prevalence of β-thalassaemia in the region.

In sub-Saharan Africa, there are increasing efforts to screen and diagnose genetic diseases at birth from...
Fig. 2 Mutations in the β-globin gene can be accurately phased across multiple exons due to long-read nanopore sequencing. Top: The c.92+1G>A variant in sample 144 is phased with the wild-type allele at the Glu7 residue. Centre and bottom: In both samples 245 and 462, the stop-gain variant is in phase with the wild-type allele at Glu7.

Table 3 Cost analysis of sickle cell and β-thal screening by nanopore sequencing. Cost estimates are based on 24 samples per library, and 8 libraries sequenced per flowcell.

| Item                          | Reactions per item | Cost per reaction | No. required per sample | Cost/test |
|-------------------------------|--------------------|-------------------|-------------------------|-----------|
| QiAmp DNA blood mini kit      | 250                | £1.86             | 1                       | £1.86     |
| Enrichment Step 1             | 200                | £0.72             | 1                       | £0.72     |
| Enrichment Step 2             | 1000               | £0.93             | 2                       | £1.86     |
| Enrichment Step 3             | 50                 | £9.24             | 0.04                    | £0.41     |
| PCR barcoding kit             | 960                | £1.42             | 1                       | £1.42     |
| Ligation sequencing kit       | 6                  | £80.00            | 0.04                    | £3.33     |
| SpotON flowcell               | 192                | £1.98             | 1                       | £1.98     |

£11.57

ONT Oxford Nanopore Technologies
DBS. These include SCD and thalassaemia. These efforts need to be complemented by accurate, simple, reliable, and affordable testing which will be used to diagnose multiple conditions. In this study we tested the use of DNA from both whole blood and DBS, the latter being the preferred method that may ensure inclusion of samples from remote locations and better fits the newborn screening algorithm. From our findings, DNA extracted from DBS generated MinION sequencing data of equivalent quality to whole-blood derived DNA.

This enabled us to address the big challenge of inconclusive results in NBS caused by incomplete Hb switching or co-inheritance of other haemoglobin variants. For example, we identified an individual with a heterozygous IVS1-1G>A variant in trans with a heterozygous Glu-7Val mutation, as a result of using a long-read sequencing approach.

Although it is known that accurate diagnosis of genetic conditions is achieved through genotyping or sequencing, the required investment, cost, and expertise for conducting sequencing and data analysis have been challenging to put in place. The developed assay has proven to be feasible due to the minimum up-front investment required and low running cost. Also, with minimum hands-on wet lab training from the Oxford Molecular Diagnostic Centre (OMDC), local laboratory personnel at MUHAS can perform the assay. Most importantly, the technology does not require procurement and maintenance of expensive capital equipment and, although bioinformatics data analysis will require further rigorous standardisation, it can be securely performed in the cloud. This project has served as a platform for training by providing relevant sequencing data for trainees in bio-informatics. The training was delivered online and included the use of cloud servers, introduction into analysis tools and clinical variant identification and interpretation. Our long-term financial sustainability plan is based on a local social enterprise spin-out that delivers sequencing services to aid diagnostics and research.

**Conclusion**

In a population such as Tanzania with a potential high prevalence of SCD coupled with other haemoglobin variants, DNA analysis allowing resolution of uncertain cases and confirmation of all positive cases is mandatory before pre-marital counselling and initiation of therapy. We show that single-molecule long-read sequencing, such as that offered by the MinION platform (Oxford Nanopore Technologies, Oxford, UK) enables the identification of SCD and other haemoglobin variants as well as the resolution of complex genetics that cannot be readily identified by HPLC and IEF. Its ability to sequence DNA from DBS and whole blood rapidly, at low initial cost, and without the need for initial capital investment make it an attractive DNA sequencing device to support haemoglobin research and diagnosis in low-middle-income countries such as Tanzania.

**Abbreviations**

DBS: Dried Blood Spot; DNA: Deoxyribonucleic acid; HPLC: High-Performance Liquid Chromatography; IEF: Isoelectric focusing; MNH: Muhimbili National Hospital; MUHAS: Muhimbili University of Health and Allied Sciences; NBS: Newborn screening; POC: Point of Care; VAF: Variant allele frequency; WB: Whole Blood.

**Acknowledgements**

The authors thank Prof Lucio Luzzatto’s ongoing support and valuable input in writing this paper. We also thank the staff at Muhimbili National Hospital, Temereke Regional Hospital, Muhimbili University of Health and Allied Sciences, and the Sickle Cell Program for their efforts in making this project a success.

**Authors’ contributions**

AS, SN, AB, and HC designed the study. AB, HC, and EJ collected the data. AB analysed and interpreted the data. HC, AB, SN, and AS drafted the manuscript. All authors contributed to the draft of the manuscript and approved the final draft.

**Funding**

This work was supported by the UK Medical Research Council’s fund, the Wellcome Trust’s Oxford Translational research fund, theOrganization for Women in Science for Developing world fund (OWSD), award number 4500384860, and the UKAid/Department for International Development (DFID) through the Human Development Innovation Fund (HDF) [HW2.0003].

**Availability of data and materials**

The data supporting the findings of this study are available within the article. Raw data that support the findings of this study are available from the corresponding author upon a reasonable request.

**Declarations**

**Ethics approval and consent to participate**

Ethical approval was granted by the MUHAS research and publications committee with reference number 2019-8-20/DA.282/298/01. C. Informed consent was obtained from all the participants including consent from parents of participants below 16 years. All the methods were performed in accordance with MUHAS research and publications committee.

**Consent for publication**

Written informed consent for publication of the clinical details was obtained from both the adult study participants and consent from parents of the children below 18 years. A copy of consent form is available to review by the Editor.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Sickle cell programme, Department of haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

2 Oxford Molecular Diagnostics Centre, University of Oxford, Oxford, UK.

3 Department of Biological Sciences, Dar es Salaam University College of Education (DUCE), Dar es Salaam, Tanzania.

**Received:** 20 August 2021  **Accepted:** 22 November 2021  **Published online:** 16 December 2021
References

1. Eaton WA, Hofrichter J. Sickle cell haemoglobin polymerization. Adv Protein Chem. 1990;40:63–279 Accessed December 2, 2018. http://www.ncbi.nlm.nih.gov/pubmed/2195851.

2. Old JM. Screening and genetic diagnosis of haemoglobin disorders. Blood Rev. 2003; https://doi.org/10.1016/S0268-960X(02)00061-9 Published online.

3. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global Burden of Sickle Cell Anaemia in Children under Five, 2010-2050: modelling based on demographics, excess mortality, and interventions. Plos Med 2013;10(7). https://doi.org/10.1371/journal.pmed.1001496.

4. Ware RE, de Montalembert M, Thilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10109):311–23. https://doi.org/10.1016/S0140-6736(17)30193-9.

5. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142–51. https://doi.org/10.1016/S0140-6736(12)61229-X.

6. Serjeant G. World sickle cell day: lessons for India. Indian J Med Res. 2017;145(6):705. https://doi.org/10.1043/ijmtrr.1208_17.

7. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: A neglected cause of early childhood mortality. Am J Prev Med. 2011;41(6 SUPPL.4):S398. https://doi.org/10.1016/j.amepre.2011.09.013.

8. Makani J, Cox SE, Soka D, et al. Mortality in sickle cell anaemia in Africa: a prospective cohort study in Tanzania. PLoS One. 2011;6(2):e14699. https://doi.org/10.1371/pone.0014699.

9. Thein SL, Waincooart JS, Sambpiero M, et al. Association of thalassemia intermedia with a beta-globin gene haplotype. Br J Haematol. 1987;65(3):367–73. https://doi.org/10.1111/j.1365-2141.1987.tb06870.x.

10. WHO. Sickle-Cell Anaemia Report by the Secretariat Prevalence of Sickle-Cell Anaemia., 2006.

11. Canning DM, Huntsman RG. An assessment of Sickleled as an alternative to the sickling test. J Clin Pathol. 1970;23(8):736–7. https://doi.org/10.1136/jcp.23.8.

12. Smart LR, Ambrose EE, Raphael KC, et al. Simultaneous point-of-care detection of anemia and sickle cell disease in Tanzania: the RAPID study. Ann Hematol. 2018;97(2):239–46. https://doi.org/10.1007/s00277-017-3182-8.

13. Kanter J, Telen MJ, Hoppe C, Roberts CL, Kim JS, Yang X. Validation of a novel point of care testing device for sickle cell disease. BMC Med. 2013;13(1):225. https://doi.org/10.1186/1475-2875-8-271.

14. lamps, a simple, rapid, low-cost diagnostic test for sickle cell disease. Lab Chip. 2013;13(8):1464–7. https://doi.org/10.1039/c3lc41302k.

15. Kanter J, Telen MJ, Hoppe C, Roberts CL, Kim JS, Yang X. Validation of a novel point of care testing device for sickle cell disease. BMC Med. 2015;13(1):225. https://doi.org/10.1186/s12916-015-0473-6.

16. Mccann PT, Schaefer BA, Panigaruas M, Howard TA, Ware RE. Characteristics of a rapid, point-of-care lateral flow immunoassay for the diagnosis of sickle cell disease. Am J Hematol. 2016;91(2):205–10. https://doi.org/10.1002/ajh.24232.

17. Quick J, Loman NJ, Duraffour S, et al. Real-time, portable genome sequencing for Ebola surveillance. Nature. 2016;530(7589):228–32. https://doi.org/10.1038/nature16996.

18. Thernell BL, Hoppe C, Mann MY, et al. Newborn Screening for Hemoglobinopathies Suggested Citation, 2019.

19. Bowden R, Davies RW, Heger A, et al. Sequencing of human genomes with nanopore technology. Nat Commun. 2019;10(1):1869. https://doi.org/10.1038/s41467-019-09637-5.

20. Schubert S, van Luttikhuizen J, Auber B, et al. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: high frequency of FANCM pathogenic variants. Int J Cancer. 2019;144(11):2683–94. https://doi.org/10.1002/ijc.31992.

21. Euskirchen P, Bielle F, Labreche K, et al. Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. Acta Neuropathol. 2017;1–13.

22. Leija-Salazar M, Sedlazeck FJ, Toffoli M, et al. Evaluation of the detection of GBA missense mutations and other variants using the Oxford Nanopore MinION. Mol Genet Genomic Med. 2019;7(3). https://doi.org/10.1002/mg3.564.

23. Treisman R, Orkin SH, Maniatis T. Specific transcription and RNA splicing defects in five cloned β-thalassaemia genes. Nature. 1983;302(5909):591–6. https://doi.org/10.1038/302591a0.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.